Open access
Aug 2026
Antiviral Activity of Nirmatrelvir Against Contemporary SARS-CoV-2 Variants.
Nirmatrelvir, the active antiviral component of Paxlovid®, was evaluated for potency against 20 genetically diverse and clinically relevant SARS-CoV-2 variants circulating between 2020 and 2024. Robust in vitro antiviral activity was demonstrated against all tested variants, with only modest reductions in susceptibilit...
Irina Yurgelonis, Devendra K. Rai, Jonathan T. Lee et al.
· Antiviral Research · 0 citations